Bianka Perge
Overview
Explore the profile of Bianka Perge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perge B, Papp G, Boi B, Markoth C, Bidiga L, Farmasi N, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941336
: Lupus nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE). Chronic kidney disease (CKD) and its progression into end-stage renal disease (ESRD) are...
2.
Perge B, Papp G, Boi B, Nagy N, Gaspar-Kiss E, Tarr T
Biomedicines
. 2024 Sep;
12(9).
PMID: 39335630
Lupus nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE). The aim of our retrospective cohort study was to compare the clinical characteristics, therapy,...
3.
Nagy N, Boi B, Papp G, Fiak E, Gaspar-Kiss E, Perge B, et al.
Biomedicines
. 2024 Mar;
12(3).
PMID: 38540143
In systemic lupus erythematosus (SLE), cardiovascular complications are among the leading causes of death. Cardiovascular risk in SLE is even higher in the presence of antiphospholipid antibodies or secondary antiphospholipid...
4.
Dioszegi A, Lorincz H, Kaali E, Soltesz P, Perge B, Varga E, et al.
Biomolecules
. 2023 Mar;
13(3).
PMID: 36979336
Background: Impaired lipid metabolism contributes to accelerated inflammatory responses in addition to promoting the formation of atherosclerosis in systemic lupus erythematosus (SLE). We aimed to evaluate the lipid profile, inflammatory...
5.
Rakoczi E, Perge B, Vegh E, Csomor P, Pusztai A, Szamosi S, et al.
Joint Bone Spine
. 2016 Mar;
83(6):675-679.
PMID: 26995488
Objectives: To prospectively evaluate the immunogenicity of a 13-valent conjugated pneumococcal vaccine (PCV13) in rheumatoid arthritis (RA) patients undergoing etanercept therapy. Methods: Twenty-two RA patients treated with etanercept (ETA) in...